Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
Perez-Molina, José A, PhD, Rubio, Rafael, PhD, Rivero, Antonio, PhD, Pasquau, Juan, MD, Suárez-Lozano, Ignacio, MD, Riera, Melcior, MD, Estébanez, Miriam, PhD, Santos, Jesús, PhD, Sanz-Moreno, José, PhD, Troya, Jesús, MD, Mariño, Ana, MD, Antela, Antonio, PhD, Navarro, Jordi, MD, Esteban, Herminia, BSB, Moreno, Santiago, PhD
Published in The Lancet infectious diseases (01.07.2015)
Published in The Lancet infectious diseases (01.07.2015)
Get full text
Journal Article